InvestorsHub Logo
Followers 117
Posts 20162
Boards Moderated 0
Alias Born 06/13/2011

Re: None

Sunday, 09/06/2020 1:40:22 AM

Sunday, September 06, 2020 1:40:22 AM

Post# of 423548


Amarin generic competitors to be constrained by supply chains, says Northland Northland analyst Carlton Byrnes reiterates his Outperform rating on Amarin shares as he believes the threat from generic Vascepa entrants will be limited by supply chain constraints and challenges with wholesaler distribution. The analyst, who anticipates Vascepa will "retain the lion's share of icosapent ethyl sales well into 2022 and likely beyond," also noted that he expects Vascepa commercialization in the EU in 2021.

Read more at:
https://thefly.com/n.php?id=3156182



Kiwi
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News